<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953936</url>
  </required_header>
  <id_info>
    <org_study_id>2021（202）</org_study_id>
    <nct_id>NCT04953936</nct_id>
  </id_info>
  <brief_title>β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults</brief_title>
  <official_title>β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults During Weight Loss: a Randomized Double-blind Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness and safety of HMB-enriched&#xD;
      nutritional supplements for improving muscle mass and muscle function in Chinese adults with&#xD;
      obesity during the weight loss process using calorie restriction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change in whole-body skeletal muscle mass (SMM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The whole-body skeletal muscle mass (SMM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change in appendicular skeletal muscle mass (ASMM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in trunk skeletal muscle mass (TSMM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in total body fat mass (BFM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in total appendicular body fat mass (ABFM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in trunk body fat mass (TBFM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in basal metabolic rate (BMR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in phase angle (PA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in body weight (BW)</measure>
    <time_frame>12 weeks</time_frame>
    <description>These data will be measured using InBody 770 (Biospace Co., Seoul, Korea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in handgrip strength (HGS)</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>A trained nurse will measure HGS using a digital handheld dynamometer (EH101; Xiangshan Inc, Guangdong, China) to the nearest 0.1 kg .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in waist circumference</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>A trained nurse will measure waist circumference using a tape at the level midway between the lower rib margin and the iliac crest with the participant breathing out gently.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in hip circumference</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Hip circumference was measured as the maximum circumference over the buttocks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in physical activity</measure>
    <time_frame>From the beginning to weeks 3, 6, 9, and 12.</time_frame>
    <description>It will be measured using self-reported International Physical Activity Questionnaire Short Form (IPAQ-SF).The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. Long (5 activity domains asked independently) and short (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health related physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in the score of the sit-to-stand test</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>A trained nurse will perform the 30-second sit-to-stand test ,which is a classic test for measuring the performance of lower extremity muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in energy intake</measure>
    <time_frame>From the beginning to weeks 3, 6, 9, and 12</time_frame>
    <description>It will be measured for all participants using the self-reported Food Frequency Questionnaire (FFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in lipid profiles</measure>
    <time_frame>12 weeks</time_frame>
    <description>It will be tested using standard method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>It will be tested using standard method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in fasting insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>It will be tested using standard method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>It will be tested using standard method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in albumin</measure>
    <time_frame>12 weeks</time_frame>
    <description>It will be tested using standard method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>HMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HMB-enriched Nutritional Supplements</intervention_name>
    <description>The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.</description>
    <arm_group_label>HMB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (maltodextrin 65 g once daily) with the same package as the intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Caloric Restrition Diet</intervention_name>
    <description>Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies</description>
    <arm_group_label>HMB</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women aged 30-50 years&#xD;
&#xD;
          2. Currently having obesity defined by body mass index (BMI) ≥ 28 kg/m2 (based on&#xD;
             measured body weight and height at booking, using validated scales)&#xD;
&#xD;
          3. Having an intention to lost weight via caloric restriction&#xD;
&#xD;
          4. Apparently healthy and able to walk independently&#xD;
&#xD;
          5. Able to eat independently to meet their energy needs&#xD;
&#xD;
          6. Without significant body weight change in the last 6 month (less than 5% change in&#xD;
             body weight)&#xD;
&#xD;
          7. Having sedentary habit defined by Sedentary Behavior Research Network&#xD;
&#xD;
          8. Able to collaborate with the research staff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having a history of intolerance to enteral nutrition, food (e.g., lactose&#xD;
             intolerance), or being allergic to the components of our HMB-enriched nutritional&#xD;
             supplements (e.g., soy or corn);&#xD;
&#xD;
          2. Having any implants (e.g., pacemakers);&#xD;
&#xD;
          3. Current use of other nutritional supplements or drugs that may have an impact on the&#xD;
             effectiveness of the intervention (e.g., glucocorticoids, antineoplastic drugs,&#xD;
             antituberculosis drugs, sedatives, antipsychotics, muscle relaxants, monoamine oxidase&#xD;
             inhibitors, antibiotics) within 3 months prior to enrollment;&#xD;
&#xD;
          4. Secondary obesity caused by diseases (e.g., hypothalamic diseases and&#xD;
             hypercortisolism) or drugs (e.g. glucocorticoids, insulin, tricyclic antidepressants);&#xD;
&#xD;
          5. Clinically visible edema;&#xD;
&#xD;
          6. Trauma, surgery, hospitalization, fall, or fracture within 6 months prior to&#xD;
             enrollment;&#xD;
&#xD;
          7. Pregnancy, having pregnancy plans, or lactation;&#xD;
&#xD;
          8. Individuals who are participating in other clinical trials; any acute illness (e.g.,&#xD;
             acute infection, myocardial infarction, arrhythmia, myocarditis, appendicitis, etc.);&#xD;
&#xD;
          9. Swallowing disorders; abnormal thyroid function (including hyperthyroidism and&#xD;
             hypothyroidism);&#xD;
&#xD;
         10. Having a history of diabetes, respiratory diseases, cardiovascular diseases,&#xD;
             uncontrolled hypertension, kidney diseases, digestive system diseases, renal&#xD;
             insufficiency, mental illness, neurological diseases, hematologic diseases, liver&#xD;
             diseases (except for fatty liver), chronic infection (e.g., tuberculosis), immune&#xD;
             system diseases, joint disorders, any type of tumor;&#xD;
&#xD;
         11. Alcohol consumption over two standard alcoholic beverages (20 g of alcohol/day);&#xD;
&#xD;
         12. Difficulty to comply with the study protocol;&#xD;
&#xD;
         13. Other conditions that indicate the individuals are inappropriate for participation in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Yang</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiaojiao Jiang</last_name>
    <role>Study Director</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuxaing Liang</last_name>
    <phone>0086-13982250862</phone>
    <email>yx45liang@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610064</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 12, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Yuxiang Liang</investigator_full_name>
    <investigator_title>Physiotherapist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

